Fennec Appoints Shubh Goel as Chief Commercial Officer
September 09, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
August 09, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE)...
Fennec Announces Results of Annual Meeting
June 19, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., June 19, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results
May 09, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 ...
Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
March 13, 2019 06:19 ET
|
Fennec Pharmaceuticals Inc.
Initiated rolling New Drug Application to U.S. FDA for PEDMARKTMSecured $12. 5 million debt financing to support a potential commercial launch Strong financial position with $22.8 million in cash and...
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
February 04, 2019 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™
December 20, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. ...
Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting
November 16, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results
November 13, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTMTargeting US approval of PEDMARKTM in the second half of 2019Strong financial position with $24.5 million in cash and no debt...
Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City
September 26, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...